The vast majority of thyroid cancers of follicular origin (TC) have a very favourable outcome,
but 5–10% of cases will develop metastatic disease. Around 60–70% of this subset, hence …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer.
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …

Abstract Purpose of Review While vascular endothelial growth factor receptor inhibitors
(VEGFRis) have dramatically improved cancer survival, these drugs cause hypertension in a …

Thyroid cancer is the most common endocrine malignancy. Most thyroid cancer types
respond well to conventional treatment consisting of surgery and radioactive iodine (RAI) …

Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential
role in the molecular pathways, leading to cell survival and differentiation. Consequently …

In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer
with multikinase inhibitors, much has changed in the landscape of this heterogeneous …

Tumor progression and immune evasion result from multiple oncogenic and
immunosuppressive signals within the tumor microenvironment. The combined blockade of …

Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in
cancer therapy. Displaying activity in multiple solid tumors, it has been approved in …

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

Lenvatinib is a multikinase inhibitor of vascular endothelial growth factor (VEGF) receptors 1–
3, fibroblast growth factor receptors 1–4, RET, KIT, and platelet-derived growth factor …